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Neutralizing activityGlycosylation plays important roles in gp120 structure and HIV-1 immune evasion. In the current study, we
introduced deglycosylations into the 24 N-linked glycosylation sites of a R5 env MWS2 cloned from semen
and systematically analyzed the impact on infectivity, antigenicity, immunogenicity and sensitivity to entry
inhibitors. We found that mutants N156-T158A, N197-S199A, N262-S264A and N410-T412A conferred
decreased infectivity and enhanced sensitivity to a series of antibodies and entry inhibitors. When mice
were immunized with the DNA of wild-type or mutated gp160, gp140 or gp120; N156-T158A, N262-
S264A and N410-T412A were more effective in inducing neutralizing activity against wild-type MWS2 as
well as heterologous IIIB and CH811 Envs. In general, gp160 and gp140 induced higher neutralizing activity
compared with gp120. Our study demonstrates for the ﬁrst time that removal of individual glycan N156,
N262 or N410 proximal to CD4-binding region impairs viral infectivity and results in enhanced capability
to induce neutralizing activity.
© 2011 Elsevier Inc. All rights reserved.Introduction
The ideal strategy for HIV-1 prevention is an effective prophy-
lactic vaccine. Seeking an antigen capable of inducing broad and
potent neutralizing antibody is the primary goal of prophylactic
vaccine development. HIV-1 gp120 is considered the principal
target for preventative vaccines (Graham and Wright, 1995;
Pantophlet and Burton, 2006). However, HIV-1 has evolved effec-
tive mechanisms to escape antibody neutralization. For instance,
gp120 is highly glycosylated, with carbohydrates accounting for as
much as 50% of its mass. Such carbohydrate moieties are proposed
to act as shields occluding highly immunogenic epitopes on gp120.
Early vaccines based on unmodiﬁed gp120 monomers induced
limited breadth of neutralization, only effective against T cell line
adapted isolates (Berman et al., 1990; Cooney et al., 1993; Gilbert
et al., 2005; Schultz and Bradac, 2001) rather than primary strains
(Bures et al., 2000; Connor et al., 1998; Flynn et al., 2005;
Hanson, 1994; Mascola et al., 1996; Matthews, 1994; Pitisuttithum
et al., 2006). Although there is growing evidence that trimeric
gp140 may represent a better vaccine candidate (Beddows et al.,Virology, Wuhan Institute of
an Zhongqu, Wuhan 430071,
rights reserved.2007; Earl et al., 2001; Jeffs et al., 2004; Kim et al., 2005), develop-
ment of an effective preventive vaccine remains elusive.
The carbohydrate moieties on gp120 are synthesized by the
infected host cells and act as “shields” to mask the conserved CD4
binding site. gp120 promotes virus entry into host cells by sequen-
tial binding to receptor CD4 and co-receptor CCR5 or CXCR4. Dele-
tion of these glycans may modulate the recognition of receptor or
co-receptor binding sites masked by carbohydrates. Several studies
have described that modiﬁcation of gp120 glycosylation sites affects
viral entry by interfering with receptor binding (Dunfee et al.,
2007; Malenbaum et al., 2000). For instance, removal of several in-
dividual N-linked glycosylation sites of HXB2 gp120 in the canoni-
cal Asn-x-Ser/Thr sequence impairs viral infection (Lee et al.,
1992). Deglycosylation at a single N-linked glycan site N197 alters
the steric conﬁguration of CD4 binding sites and promotes CD4-
independent infection of HIV-1 (Kolchinsky et al., 2001). In addi-
tion, N-linked glycosylation sites may be involved in regulating
the interaction between CD4 and co-receptors CCR5 (Ly and
Stamatatos, 2000; Ogert et al., 2001; Pollakis et al., 2001) or
CXCR4 (Dumonceaux et al., 2001; Polzer et al., 2001).
The current challenge for design of a protective HIV-1 vaccine
based on gp120 is to develop suitable strategies to enhance its an-
tigenicity and immunogenicity. Although intense investigation has
revealed that the antigenicity of HIV-1 Env can be changed by
removing certain glycans (Cole et al., 2004; Duenas-Decamp et al.,
Table 1












88 N88-T90A NVT→NVA 68% 5.81
N88-T90S NVT→NVS 83% ND
131 N131-T133A NST→NSA 74% 0.82
N131-T133S NST→NSS 86% ND
134 N134-T136A NAT→NAA 76% 1.25
N134-T136S NAT→NAS 89% ND
140 N140-T142A NNT→NNA 72% 6.25
N140-T142S NNT→NNS 82% ND
141 N141-S143A NTS→NTA 78% 5.65
N141-S143T NTS→NTT 74% ND
156 N156-T158A NCT→NCA 15% (~7 fold↓) 0.42
N156-T158S NCT→NCS 57% ND
160 N160-T162A NVT→NVA 78% 5.30
N160-T162S NVT→NVS 64% ND
186 N186-S188A NES→NEA 102% 6.13
N186-S188T NES→NET 112% ND
197 N197-S199A NTS→NTA 61% 0.69
N197-S199T NTS→NTT 73% ND
230 N230-T232A NKT→NKA 73% 5.32
N230-T232S NKT→NKS 99% ND
234 N234-T236A NGT→NGA 94% 5.99
N234-T236S NGT→NGS 99% ND
241 N241-S243A NVS→NVA 87% 5.63
N241-S243T NVS→NVT 96% ND
262 N262-S264A NGS→NGA 25% (~4 fold↓) 0.77
N262-S264T NGS→NGT 87% ND
276 N276-T278A NIT→NIA 90% 5.99
N276-T278S NIT→NIS 99% ND
295 N295-T297A NCT→NCA 100% 5.55
N295-T297S NCT→NCS 112% ND
301 N301-T303A NNT→NNA 93% 5.69
N301-T303S NNT→NNS 95% ND
332 N332-S334A NIS→NIA 71% 1.66
N332-S334T NIS→NIS 74% ND
339 N339-T341A NKT→NKA 71% 1.47
N339-T341S NKT→NKS 79% ND
356 N356-T358A NKT→NKA 106% 5.31
N356-T358S NKT→NKS 109% ND
386 N386-S388A NTS→NTA 103% 5.62
N386-S388T NTS→NTT 109% ND
392 N392-T394A NST→NSA 105% 6.36
N392-T394S NST→NSS 114% ND
410 N410-T412A NST→NSA 77% 1.30
N410-T412S NST→NSS 80% ND
448 N448-T450A NIT→NIA 21% (~5 fold↓) 1.20
N448-T450S NIT→NIS 90% ND
462 N462-T464A NRT→NRA 113% 5.15
N462-T464S NRT→NRS 111% ND
465 N465-T467A NET→NEA 63% 5.68
N465-T467S NET→NES 71% ND
Bold data imply that mutants had signiﬁcantly decreased infectivity, or increased/
decreased sensitivity to antibodies or entry inhibitors.
Data are representative of at least three independent experiments (↓ decrease).
a IC50 (μg/ml).
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whether and how deglycosylations affect the immunogenicity of
Env has not been characterized systematically. Certain site speciﬁc
deglycosylations or their combinations on HIV-1 Env have been
suggested to enhance the induction of neutralizing activity
(Bolmstedt et al., 1996). Similar results have also been observed
with SIV Env (Mori et al., 2005; Reitter et al., 1998). In particular,
multiple deglycosylation combinations in the V1V2 region of HIV-
1 89.6 Env induce neutralizing activity more effectively than the
wild-type (WT) Env (Quinones-Kochs et al., 2002). Moreover, dele-
tion of a single glycosylation site at N197 of HIV-1 89.6 gp140
trimer enhances the ability to induce neutralizing responses (Li et
al., 2008). However, the effect of deglycosylations on immunogenic-
ity needs to be clariﬁed as most previous studies deleted glycans by
introducing a conservative ﬁrst-site amino acid substitution from
Asn-x-Ser/Thr to Gln-x-Ser/Thr and were mainly based on
laboratory-adapted or clade B gp160, gp140 or gp120 (Lee et al.,
1992; Li et al., 2008; Quinones-Kochs et al., 2002). It is not clear
whether such modiﬁcation of structure and function of Env are
due to amino acid substitutions or the loss of glycans. Moreover,
the impact of removal of glycans proximal to CD4 binding region
remains to be addressed, while a systematic comparison of the
immunogenicity of gp160, gp140 and gp120 delivered via DNA
immunization has not been fully explored.
Given that sexual transmission is the leading mode of HIV-1 in-
fection worldwide, it will be important to design vaccines against
sexual transmitted isolates, in particular those clades spreading
most rapidly in the world. In the current study, we introduced a
series of conservative third-site substitutions from serine/threonine
to alanine or threonine/serine in the 24 N-linked glycosylation sites
of gp120 based on a clade C MWS2 env cloned from semen of a
subject known to have infected women by vaginal intercourse.
The strategy of using conserved third-site substitutions in the
canonical Asn-x-Ser/Thr sequences from Ser/Thr to Ala or Thr/Ser
allows parallel assessments of glycan mutants and amino acid
mutants. We examined the effect of removal of individual gp120
glycans on viral infectivity as well as sensitivity to antibodies,
CCR5 antagonists and carbohydrate-binding agents (CBAs). Addi-
tionally, we compared the immunogenicity of gp160, gp140 and
gp120 by vaccination of mice with corresponding DNA.
Results
Infectivity of Env glycan mutants
To better understand the roles of Env glycans, we constructed
deglycosylated mutants based on a primary clade C R5 MWS2 Env
cloned from semen. Subsequent experiments were carried out in an
infection assay using Env pseudotyped viruses to infect TZM-bl cells.
Glycan mutants N156-T158A, N262-S264A and N448-T450A showed
a sharp reduction of infectivity, demonstrating ~15%, ~25% and ~20%
infectivity ofWT, respectively, while other glycanmutatans had infec-
tivity range from61% to 113% of theWT (Table 1 and Fig. 1A). A similar
pattern of infectivity was observed when U87.CD4.CCR5 cells were
infected with Env pseudotyped virus (Fig. 1A).
To assess whether the reduction of pseudotype-virus infectivity
was due to decreased protein expression, we detected the expression
of Env in HeLa cells by Western blot analysis. We analyzed the gray-
scale values using Bio-Rad Discovery software. The relative gp160 ex-
pression levels of WT, N156-T158A, N262-S264A and N410-T412A
were 100, 115, 87 and 129, while the relative infectivity levels of
WT, N156-T158A, N262-S264A and N410-T412A were 100, 15, 25
and 77, respectively (Fig. 1B and Table 1), indicating that there was
no correlation between the level of protein expression and viral infec-
tivity. We further examined cell surface expression of Env by ﬂowcytometry. The expression levels of WT, N156-T158A, N262-S264A
and N410-T412A Env were similar as detected by HIV-IG (Fig. 1C).
We also assessed expression using the PG9 MAb shown to recognize
overlapping epitopes preferentially expressed on the membrane-
anchored trimeric Env with its neutralization activity dependent on
glycan N160 and to a lesser extent glycan N156 (Davenport et al.,
2011; Doores and Burton, 2010; Walker et al., 2009). At the antibody
concentration used, we did not observe signiﬁcant difference in terms
of cell surface expression when PG9 (Fig. 1C) was used to detect the
expression of WT and glycan mutants. Our data together indicate
that the decreased infectivity of Env glycan mutants is unlikely due
to the reduction of Env expression.
To conﬁrm that our observations were glycan speciﬁc rather than
due to amino acid change, we constructed a panel of Env mutants by
third-site substitution from Ser to Thr or Thr to Ser at the N-linked
Fig. 1. Infectivity of MWS2 Env glycan mutants in pseudotyped virus infection and
expression of MWS2 Env glycan mutants. (A) Stocks of pseudotyped reporter viruses
were prepared by co-transfecting 293 T cells with Env expression constructs and
pSG3ΔEnv or pNL4-3.Luc.R-E- plasmid for 48 h and then harvested. TZM-bl or U87.
CD4.CCR5 cells were infected with 50 μl pseudotyped virus. The luciferase activity of
cell lysates was determined following infection for 48 h. The infectivity of WT Env
pseudotyped virus in medium alone was set to 100%. Data are representative of 3 inde-
pendent experiments, with each determination performed in triplicate (mean±SD).
(B) Expression of MWS2 Env glycan mutants. HeLa cells were transfected with Env
expression constructs or pcDNA3.1 for 48 h. Transfectants were harvested, lysed and
resolved in 12% SDS-PAGE. Western blot analyses were carried out by detecting with
human immunoglobulins pooled from HIV+patients (HIV-IgG) and HRP-conjugated
secondary antibody. Immunoreactive bands were revealed by ECL and visualized by a
CCD camera. One out of three experiments is shown. (C) Cell surface expression of
Env. 293T cells were transfected with Env expression constructs or pcDNA3.1 for
48 h. Cell surface expression of Env was assessed by ﬂow cytometry. One out of three
experiments is shown.
Fig. 2. Sensitivity to HIV-IG, CD4-IgG2 and 17b of WT and Env mutants in pseudotyped
virus infection. Stocks of pseudotyped reporter viruses were prepared by co-
transfecting 293 T cells with Env expression constructs and plasmid pSG3Δenv for
48 h and then harvested. TZM-bl cells were infected with 200 TCID50 pseudotyped
viruses in the presence of serially diluted (A) HIV-IG or (B) CD4-IgG2, or monoclonal
antibody 17b. The luciferase activity of cell lysates was determined following infection
for 48 h. Neutralization was calculated as the percentage inhibition of viral infectivity.
The infectivity of pseudotyped virus in medium alone was set to 100%. Data shown are
representative of three independent experiments, with each determination performed
in triplicate (Mean±SD).
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T158A, N262-S264A and N448-T450A, the infectivity of N156-T158S,
N262-S264T and N448-T450S was largely maintained (Table 1). As
infectivity is closely related with the steric conﬁguration of Env,
these data suggest that removal of glycans, in particular at N156,
N262 or N448, is likely to have modiﬁed the structure and function
of the HIV-1 Env.Antibody sensitivity of Env glycan mutants
The N-linked glycan sites on gp120 are highly conserved, having
been dubbed as being on the “silent face” of gp120 (Kwong et al.,
1998; Wyatt and Sodroski, 1998). Such carbohydrates can render
the underlying protein surface invisible to humoral immunity
(Pantophlet and Burton, 2006; Wyatt and Sodroski, 1998); deple-
tion of glycans could make gp120 more accessible to antibodies.
To test this hypothesis, we examined the sensitivity of the 24
MWS2 Env glycan mutants to HIV-IG. The IC50 of HIV-IG against
WT was 5.20 μg/ml, whereas N131-T133A, N134-T136A, N156-
T158A, N197-S199A, N262-S264A, N332-S334A, N339-T341A,
N410-T412A and N448-T450A mutants demonstrated enhanced
sensitivity to HIV-IG, with IC50 values of 0.82, 1.25, 0.42, 0.69,
0.77, 1.66, 1.47, 1.30 and 1.20 μg/ml, respectively (Fig. 2A and
Table 1). Other glycan mutants had similar sensitivity to HIV-IG as
that of WT. Our data suggest that deglycosylation at these sites
may increase the number or exposure of available neutralization
epitopes on gp120 to antibodies which already exist in human im-
munoglobulins from HIV+individuals.
To further investigate the signiﬁcance of these glycosylation
sites, we retrieved gp160 sequences from the HIV database
(http://hiv-web.lanl.gov) and analyzed the conservation level of
100 X. Huang et al. / Virology 423 (2012) 97–106glycosylation sites in the gp120 region of clade A, B, C and D Envs.
More than half of the glycosylation sites have a conservation ratio
over 80% (Supplementary Fig. 1). In particular, N156, N197 and
N262 are highly conserved, with an identity greater than 88%. In
comparison, N410 is signiﬁcantly less conserved. Subsequently,
experiments were focused on N156-T158A, N197-S199A, N262-
S264A and N410-T412A Env mutants because the role of these gly-
cans in infection and antigenicity has yet to be deﬁned.
To elucidate the potential exposure of neutralizing epitopes
induced by removal of speciﬁc gylcans, we carried out infection ex-
periments using a range of well-characterized MAbs and CD4-IgG2
(Pro-542). The neutralization sensitivity of N156-T158A and N197-
S199A to CD4-IgG2, which recognizes conserved CD4 binding sites,
was signiﬁcantly augmented, while N410-T412A did not alter suscep-
tibility to CD4-IgG2 (Fig. 2B and Table 2). However, N262-S264A de-
creased the sensitivity to CD4-IgG2 and showed slightly decreased
sensitivity to 4E10, a monoclonal antibody that recognizes the gp41
sequence NWFDIT, conserved among many HIV-1 strains, whereas
N156-T158A, N197-S199A and N410-T412A showed slightly en-
hanced sensitivity to 4E10. Compared to the WT, N262-S264A and
N410-T412A mutants showed enhanced sensitivity to a broadly neu-
tralizing MAb 2G12 (~15 and ~13-fold, respectively), the binding epi-
tope of which involves high-mannose type oligosaccharides at N295,
N332, N339, N386, N392 and N448, with the sugar chains at positions
N332, N339 and N392 being most critical (Calarese et al., 2003;
Sanders et al., 2002; Scanlan et al., 2002). N156-T158A also demon-
strated a modest increased sensitivity to 2G12 (~4-fold) while the
sensitivity of N197-S199A to 2G12 remained unaffected. N156-
T158A was signiﬁcantly sensitive to 17b in the absence of CD4.
Other mutants showed marginally enhanced sensitivity to 17b. To-
gether our results indicate that removal of these glycans may be ben-
eﬁcial to the exposure of CD4 binding sites.
Coreceptor use and sensitivity to entry inhibitors of Env glycan mutants
Previous studies by others showed that modiﬁcation of certain
glycans on gp120 affected coreceptor binding/switch or facilitatedTable 2













HIV-IgGa 0.42 0.69 0.77 1.30 5.20
CD4-IgG2a 0.05 (36↓) 0.05 (36↓) 12.72 (7↑) 1.53 1.82
17ba 2.82 >15.00 >15.00 >15.00 >15.00
2G12a 14.97 68.73 3.97 (15↓) 4.53 (13↓) 58.62
4E10a 0.63 0.62 2.76 1.05 2.51
CCR5 antagonist
Maravirocb 15.21 4.73 1.61 (17↓) 20.97 27.75
SCH-412147b 0.54 0.54 0.12 (26↓) 1.10 3.06
CMPD-167b 0.82 1.08 0.24 (28↓) 2.35 6.82
TAK-779b 204.47 102.81 (17↓) 113.91 (15↓) 679.80 1736.16
Carbohydrate binding agents
CV-Nb 0.30 0.25 0.07 (24↓) 0.34 1.70
GNAb 1.76 1.67 2.64 6.61 12.54
Bold data imply that mutants had signiﬁcantly decreased infectivity, or increased/
decreased sensitivity to antibodies or entry inhibitors.
*MWS2 showed resistance to MAbs IgG1b12, 447-52D and 2F5: 2F5 recognizes gp41
sequence ELDKWA (MWS2: ALDRWQ); IgG1 b12 recognizes epitopes on gp120
overlapping the CD4 binding region (key residues D185 and P369 changes to N185
and L369, respectively, in MWS2); 447-52D recognizes the highly conserved GPGR
sequence of the V3 loop (MWS2: GPGQ).
Data are representative of at least three independent experiments (↑ increase;
↓ decrease).
a μg/ml.
b nM.CD4-independent entry (Kolchinsky et al., 2001; Pollakis et al.,
2001; Polzer et al., 2002). We therefore examined the infectivity
of Env mutants versus WT in CHO-CCR5 and U87.CD4.CXCR4 cells,
respectively. All Envs including WT were noninfectious in these
cells (data not shown), indicating that removal of N156, N197,
N262 or N410 glycan does not result in CD4-independent infection
or coreceptor switch.
Nevertheless, in the current study, several Env mutants, in par-
ticular N156-T158A, showed enhanced neutralization sensitivity to
17b in the absence of soluble CD4 (Table 2 and Fig. 2B), suggest-
ing that deglycosylation in these sites on gp120 may be beneﬁcial
for the exposure of a CD4 induced epitope which only exists in
the CD4-liganded form of gp120. We subsequently investigated
the sensitivity of glycan mutants to a range of CCR5 antagonists
to assess whether deglycosylations also affect Env-CCR5 interac-
tion. Env glycan mutants, particularly N262-S264A, demonstrated
enhanced sensitivity to the tested CCR5 inhibitors maraviroc,
SCH-412147, CMPD-167 and TAK-779 (Table 2). These ﬁndings in-
dicate that removal of gp120 glycans may also affect gp120-CCR5
interaction.
Previous studies have shown that under the selection pressure
of CBAs, HIV-1 selectively lost multiple high-mannose type glycans
on gp120 to escape CBA inhibition (Balzarini et al., 2006; Hu et al.,
2007). Therefore we tested the sensitivity of MWS2 glycan mu-
tants to CBAs cyanovirin (CV-N) and Galanthus nivalis agglutinin
(GNA). Of interest, glycan mutants N156-T158A, N197-S199A,
N262-S264A and N410-T412A had increased sensitivity to CV-N
and GNA (Table 2). Of note, removal of high-mannose glycan
N262 demonstrated signiﬁcantly enhanced sensitivity to CV-N.
The binding sites on gp120 for CV-N and GNA have been sug-
gested to be high-mannose speciﬁc (Balzarini, 2007), whereas
N156, N197 and N410 are complex type glycans and there has
been no evidence indicating the involvement of N262 in the bind-
ing of tested CBAs (Balzarini, 2007; Balzarini et al., 2006). Our data
suggest that removal of CBA-binding unrelated glycans on gp120
may facilitate the binding of CBAs to their speciﬁc glycan residues.
Induction of enhanced neutralizing activity in mice by Env glycan
mutants
It is well documented that HIV-1 uses its glycan shields in virus-
infected individuals to avoid neutralization (Wei et al., 2003). Indeed,
removal of N197 glycan alone or multiple glycans including N156 in
the V1V2 region of 89.6 Env results in enhanced ability to induce neu-
tralizing activity (Li et al., 2008; Quinones-Kochs et al., 2002). In the
current study, we investigated whether removal of individual N156,
N262 or N410 promote neutralizing activity in a mouse model.
N197 was not included because its immunogenicity was character-
ized in a previous study (Li et al., 2008). We immunized mice
(n=9/group) with 30 μg DNA of gp160, gp140 or gp120 glycan mu-
tants three times by electroporation at 3 week intervals. We tested
the neutralization activity of sera from immunized mice against
homologous and heterologous Envs using a well-established pseudo-
typed virus neutralization system.
Ten days after the ﬁnal immunization, the gp160 and gp140
forms of N156-T158A, N262-S264A or N410-T412A elicited signiﬁ-
cantly higher levels of neutralizing activity against the homologous
WT MWS2 Env as well as heterologous X4 IIIB and primary R5
CH811 Envs (Fig. 3A). In contrast, the ability of gp120 monomer
glycan mutants in inducing neutralizing activity was much more
complex. When tested against IIIB or CH811 Env, the sera from
N156-T158A, N262-S264A or N410-T412A gp120 vaccinated mice
achieved higher neutralizing activity than those from WT gp120.
However, when tested against MWS2 Env, the neutralizing activity
elicited by gp120 mutant N156-T158A, N262-S264A or N410-T412A
was very similar to that of WT gp120. In general, gp160 and gp140
101X. Huang et al. / Virology 423 (2012) 97–106DNAs induced higher neutralizing activity compared with mono-
meric gp120 (Fig. 3B).Characterization of the neutralizing activity of mouse sera
We initially performed neutralization activity assay of sera at 3-
fold dilution of 1:20 to 1:540 against MWS2 Env pesudotyped virus.We noticed that mouse sera at lower concentration caused slight en-
hancement of virus infection in TZM-bl cells (Fig. 4A). We therefore
chose 1:20 dilution for our neutralizing experiments in accordance
with standard protocols previous established by others (Devito et
al., 2004; Monteﬁori, 2009; Radaelli et al., 2007). It is well known
that neutralization assays using mouse sera can have background
problems. To further conﬁrm the speciﬁcity of mouse sera, we tested
the neutralization activity of immunized mouse serum against VSV-G
pseudotyped virus and did not observe signiﬁcant neutralization
when mouse sera from different groups were used (Fig. 4B). 20 days
after the ﬁnal immunization, neutralizing activity in different groups
against MWS2 Env pesudotyped virus decreased to an equivalent
level (Fig. 4C). Due to the lack of homologous MWS2 Env protein,
we also examined the levels of Env-speciﬁc IgG in mouse sera by
ELISA using heterologous CN54 gp140 protein as capture antigen.
We conﬁrmed induction of gp140-speciﬁc IgG in mice vaccinated
with MWS2 gp140 DNA (Fig. 4D).
Collectively, our results illustrate that gp160 and gp140 DNAs of
N156-T158A, N262-S264A or N410-T412A are capable of inducing
neutralizing activity against homologous and, to a lesser extent,
some heterologous primary as well as laboratory-adapted isolates.Discussion
An ideal strategy to block the acquisition of HIV-1 infection is the
development of effective preventive vaccines which can generate
neutralizing antibodies against primary HIV-1 isolates, in particular
those associated with sexual transmission. Because glycans on HIV-
1 play important roles in viral infection and immune escape from
the host (Reitter et al., 1998; Wei et al., 2003), glycan modiﬁcation
may represent a rational approach to elicit protective neutralizing
antibody responses.
Deglycosylations of HIV-1 Env was previously reported to inﬂu-
ence HXB2 infectivity (Lee et al., 1992). Here we found that replace-
ment of serine or threonine with alanine in the Asn-x-Ser/Thr
glycosylation sites of MWS2 env cloned from semen, including
N262, proximal to the highly conserved core structure of CD4 binding
region on the inside, resulted in sharp reduction of HIV-1 infection.
Similar results were observed when N262 on HIV-1 BaL and IIIB
Envs was deglycosylated (Supplementary Fig. 2). The rigidity of the
highly conserved amino acid sequences of gp120 usually contribute
to the maintenance of steric conformation. Because the amino acid se-
quence of glycosylation site at N262 is very close to the core structure
of CD4 binding sites (CD4BS) on the inside (Fig. 5), depletion of glyco-
sylation site at N262 may lower the entropy for interaction of adja-
cent secondary-structure elements in C4 and C5 region involved in
CD4BS. The glycosylation is also known to affect the correct protein
folding. Deglycosylation at N262 may induce the modiﬁcation of β-
strand-turn-β-strand structure in the C2 region and impair the highly
conserved core structure of Env. Taken together, deglycosylation at
N262 may result in rearrangement of CD4BS or conformational
change of Env and further affect receptor and/or coreceptor binding.Fig. 3. Generation of neutralizing activity to site-speciﬁc deglycosylated gp160, gp140
or gp120 in mice. (A) Mice were immunized i.m. with MWS2 gp160, gp140 or gp120
DNA by electroporation and the immunization was repeated three times in 3 week
intervals. Sera were collected from mice (n=9/group) 10 days after the ﬁnal immuni-
zation and tested at a single dilution (1:20) for neutralization activity against a panel of
wild-type (WT) HIV-1 MWS2, IIIB, CH811 Env pseudotyped virus in TZM-bl cells. The
luciferase activity of cell lysates was determined following infection for 48 h. Neutral-
ization sensitivity was shown as the percentage inhibition of viral infectivity. The infec-
tivity without sera was set to 100%. Results represent mean of three duplications
(Mean±SD; –, median;…,mean). (B) Summary of mouse serum neutralizing activity
against HIV-1 MWS2, IIIB and CH811 Env pseudotyped virus at day 10 after the
ﬁnal immunization. Statistical analysis was assessed by unpaired Student's t-test.
(Mean±SEM; *, p b0.05; **, p b0.01).
Fig. 4. Characterization of the neutralizing activity of mouse sera. (A) Neutralization activity of mouse sera from gp160 or gp140 immunized animals at 3-fold dilution against
MWS2 Env pseudotyped virus was assayed in TZM-bl cells. The luciferase activity of cell lysates was determined following infection for 48 h. Neutralization sensitivity was
shown as the percentage inhibition of viral infectivity. The infectivity without sera was set to 100%. Results represent the mean±SEM of each group (n=9/group). (B) Mouse
serum neutralizing activity against HIV-1 MWS2 and VSV-G Env pseudotyped virus at day 10 after the ﬁnal immunization (Mean±SEM; n=9/group). (C) Mouse serum neutral-
izing activity against HIV-1 MWS2 Env pseudotyped virus at day 10 and 20 after the ﬁnal immunization (Mean±SEM; n=9/group). (D) gp140-speciﬁc IgG in mouse sera.
Heterologous CN54 gp140 was used as capture antigen. Endpoint titers of gp140-speciﬁc IgG in mice (n=5/group) immunized with MWS2 gp140 DNA were measured ten
days after the ﬁnal immunization. Vertical bars show mean±SEM of each group (n=9/group).
Fig. 5. The location of N262 on HIV-1 gp120 trimer. The location of N262 glycan on the
trimeric gp120 three dimensional structure (PDB ID: 3DNN) in relation to the CD4
binding sites (blue). The positions of N197 (yellow, inner domain), N262 (green,
outer domain) and N410 (purple, outer domain) are shown in the context of the crystal
structure of HIV-1 gp120. Since the V1V2 region containing residue N156 has not been
resolved, the estimated position of N156 (red, inner domain) is shown.
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decreased sensitivity to CD4-IgG2.
We observed that several of the 24 deglycan mutants showed en-
hanced sensitivity to HIV-IG (human immunoglobulins pooled from
HIV+patients). It is reasonable to conclude that such deglycosyla-
tions may increase the number or exposure of available neutralization
epitopes on gp120 to antibodies which already exist in HIV-IG. MWS2
WT Env was resistant to b12, 447-52D and 2F5, because it lacks the
key amino acid residues in the antibody epitopes. MWS2 env gene
was cloned from semen; whether there is any biological signiﬁcance
remains to be further addressed. In agreement, a previous study
revealed that transmitted or early founder HIV-1 Envs demonstrated
equivalent or modestly enhanced resistance to broadly neutralizing
antibodies (Keele et al., 2008). Although N262 is a high-mannose
type glycan, it is not the binding site of 2G12 (Sanders et al., 2002;
Scanlan et al., 2002). It is worth noting that deglycosylated mutant
N262-S264A had signiﬁcantly decreased sensitivity to CD4-IgG2,
which recognizes conserved CD4 binding sites. The modiﬁcation of
canonical glycosylation site at N262 may reduce rigidity of the nearby
amino acids or alter the structural arrangement of the neighboring
103X. Huang et al. / Virology 423 (2012) 97–106glycans, thereby allowing Env to stabilize in an abnormal conforma-
tion that is not exhibited before CD4 engagement, resulting in rear-
rangement of the key epitopes required for antibody recognization,
CD4 binding and/or membrane fusion. This is in agreement with our
observation that deglycosylation at N262 resulted in sharp reduction
of HIV-1 infection.
Deglycosylations may also affect the interaction between gp120
and its coreceptors based on the results from SF162 (Ly and
Stamatatos, 2000) and DH12 (Dumonceaux et al., 2001). We ob-
served in the present study that removal of certain glycans proxi-
mal to the CD4-binding region resulted in signiﬁcantly enhanced
sensitivity to small-molecule CCR5 inhibitors, including maraviroc,
SCH-412147, CMPD-167 and TAK-779. It is probable that removal
of the highly conserved glycosylation sites which likely modify
the conformation of CD4BS and/or Env may also affect the interac-
tion between gp120 and CCR5. In addition, the fusion kinetics may
also have been affected. Of interest, glycan mutants N156-T158A,
N197-S199A and N410-T412A had increased sensitivity to tested
CBAs, of which N262-S264A showed enhanced sensitivity to CV-N.
N156, N197 and N410 are complex-type glycans (Gallaher et al.,
1995; Leonard et al., 1990; Zhu et al., 2000) which are not recog-
nized by high-mannose speciﬁc binding CBAs (Balzarini, 2007). Al-
though N262 is a high-mannose type glycan, previous studies
revealed that, under the selection pressure of CBAs, CBA-resistant
HIV-1 variants still maintained the high-mannnose glycan N262
on gp120 (Balzarini, 2007; Balzarini et al., 2006). Therefore, N262
is unlikely to be recognized by CV-N and GNA. Deglycosylation at
N262 may rearrange the spatial structure of gp120 and increase
the exposure of CBA-targeted carbohydrates including adjacent gly-
cans N295, N332 and N448. We have recently demonstrated that
removal of N295 or N448 renders HIV-1 resistant to high-
mannose speciﬁc binding CBA grifﬁthsin, indicating the speciﬁcity
of N295 and N448 in grifﬁthsin-gp120 interaction (Huang et al.,
2011). Further understanding the effect of deglycosylations on the
sensitivity of Env to entry inhibitors may have implications for
therapeutic and prophylactic use of entry-based antiretrovirals.
Deglycosylations can affect Env immunogenicity. For instance,
removal of N197 or multiple glycans on HIV-1 89.6 Env induced en-
hanced neutralizing activity (Li et al., 2008; Quinones-Kochs et al.,
2002). Our results indicated that removal of N156, N262 or N410
alone was sufﬁcient to enhance neutralizing activity against homol-
ogous and heterologous Env pseudotyped viruses. We also con-
ﬁrmed that removal of N197 had similar effect as reported
previously (Li et al., 2008), while removal of N332 or N448 did
not inﬂuence the immunogenicity compared with WT (data not
shown). In general, gp140 DNA of glycan mutant N156, N262 or
N410 induced the highest neutralizing activity among the three
DNA forms. As suggested by others, the high glycosylation of tri-
meric molecules (4–35 trimmers per virion) shield immunogenic
epitopes on HIV-1 virion from neutralization (Swanson and
Malim, 2008). Immunization with gp120 monomer usually elicits
non-neutralizing antibodies (non-NtAbs) which target the inner do-
main of Env trimer or other epitopes not exhibited in native Env. In
contrast, glycan-removed gp140 may efﬁciently reveal immunogen-
ic epitopes that are not well exposed in native trimer. The basis for
the augmented NtAb responses induced by deglycosylated Env mu-
tants remains to be further investigated. Nevertheless, our observa-
tions add important information to the approach aiming to induce
neutralizing antibodies that recognize the functional trimeric Env
complex (Dey et al., 2007; Fouts et al., 2002; Morner et al., 2009;
Pantophlet and Burton, 2006). Given the relative poor immunoge-
nicity of HIV-1 Env DNA (Robinson, 2009), while beyond the
scope of this study, it will be important to determine whether a
heterologous DNA prime followed by boosting with matched
deglycosylated Env protein could increase the observed immune
activity reported here. Previous studies have suggested that suchheterologous DNA prime-protein boost strategies can potently in-
crease neutralization titers and breadth of activity (Vaine et al.,
2010).
Given that HIV Env is an important target for prophylactics and
therapeutics, rational modiﬁcation of Env to improve its antigenicity
and immunogenicity may provide essential information for the de-
sign of effective preventative and/or therapeutic vaccines. The ﬁnd-
ings in this study demonstrate that removal of certain glycans
proximal to CD4-binding region not only affects viral infectivity, but
also impacts Env antigenicity and immunogenicity, providing valu-
able information for vaccine development.
Materials and methods
env clones, cell lines, antibodies, CCR5 antagonists and CBAs
env clones MWS2, IIIB and BaL in pcDNA3.1 were previously de-
scribed (Hu et al., 2000b; Hu et al., 2005). CH811 env was cloned
from a blood sample isolated from a Chinese patient and the approach
for molecular cloning of env gene was previously described (Hu et al.,
2000b). 293 T cell line was purchased from the American Type Cul-
ture Collection. CHO-CCR5 cell line was previously described (Hu et
al., 2000a). TZM-bl, U87.CD4.CCR5, U87.CD4.CXCR4, VSV-G, HIV-IG,
IgG1-b12, 2G12, 447-52D, 17b and 4E10 were obtained from the
AIDS Research and Reference Reagent Program. CCR5 inhibitors mar-
aviroc, SCH-412147, CMPD-167 and TAK-779 were previously de-
scribed (Hu et al., 2010; Veazey et al., 2005). CV-N (MW 11 kDa)
was previously described (Hu et al., 2007). GNA (MW 12.5 kDa)
was purchased from Sigma. VFT1.1 expressing T7 RNA polymerase
was previously described (Hu et al., 2000b). PG9 was kindly provided
by Professor Dennis Burton.
Genetic engineering of N-linked glycan mutants of gp160, gp140 and
gp120
The envmutants were made based on a pcDNA3.1 vector contain-
ing the env gene of HIV-1 MWS2 using the QuickChange Site-Directed
Mutagenesis Kit (Agilent Tech-Stratagene). A conservative third-site
substitution from serine/threonine (Ser/Thr) to alanine (Ala) or Thr/
Ser was introduced into the 24 N-linked glycosylation sites (Asn-x-
Ser/Thr) in the gp120 region of Env, respectively. The gp140 and
gp120 mutants were created by introducing a stop codon into
gp160 mutants using high-ﬁdelity PCR. The incision enzyme site be-
tween gp120 and gp41 in gp140 was removed by site-directed muta-
genesis. Clones containing programmed mutations were identiﬁed by
sequencing. The sequence of open reading frames was conﬁrmed.
Plasmids were prepared by QIAﬁlter Maxi kit (Qiagen).
Infectivity assay and sensitivity to antibodies or inhibitors
Stocks of pseudotyped reporter viruses were prepared as de-
scribed elsewhere. In brief, 293 T cells were co-transfected with
2 μg of HIV-1 Env or VSV-G expression constructs and 3.3 μg of
pSG3Δenv or pNL4-3.Luc.R-E- plasmid DNA using Lipofectamine
2000 (Invitrogen) according to the manufacturer's instructions. Su-
pernatants containing viruses were harvested 48 h post-transfec-
tion, mixed with heat-inactivated fetal bovine serum (FBS) to a
ﬁnal concentration of 20% (V/V), ﬁltered through a 0.45 μm syringe
ﬁlter and stored at −80°C. Virus titer was determined as previously
described (Monteﬁori, 2009).
TZM-bl or U87.CD4.CCR5 cells were seeded at 6×103 cells per well
in a 96-well plate overnight and infected with 50 μl pseudotyped vi-
ruses. The luciferase activity of cell lysates was determined 48 h
post-infection. In experiments assessing inhibition, single cycle infec-
tion was conducted in TZM-bl cells in the presence of serially diluted
antibodies, entry inhibitors or CBAs.
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HeLa or 293 T cells were infected at 37°C for 1 h with or without
the vTF1.1 vaccinia virus and then transfected with gp160 constructs
for 5 h using Lipofectamine 2000 (Invitrogen). 48 h post-transfection,
cells were harvested and lysed in lysis buffer (Pierce) in the presence
of protease inhibitor cocktail (Roche). Equal amounts of proteins
were resolved by 12% SDS-PAGE and transferred onto PVDF mem-
brane (Millipore) using the Bio-Rad microassay system (Bio-Rad).
Membrane was blocked in TBS-T (TBS-0.1% Tween20) plus 5% non-
fat milk at 4 °C overnight and subsequently incubated with human
immunoglobulins pooled from HIV+patients (HIV-IgG) for 1 h at
room temperature. After washes with PBS-T, the membrane was in-
cubated with HRP-conjugated secondary antibody for 1 h at room
temperature. Following 3 washes with PBS-T, immunoreactive
bands were revealed by ECL using the Super Signal West Dura
Extended Duration Substrate (Pierce) and visualized by a CCD camera
(Alpha Innotech). The grayscale values of immunoreactive bands
were analyzed using Bio-Rad Discovery software.
Flow cytometry
293 T cells were transfected with gp160 constructs for 5 h using
Lipofectamine 2000 (Invitrogen). 48 h post-transfection, cells were
harvested and washed. Cells were stained with 1 μg HIV-IG, PG9 or
control human IgG (Serotec) in 100 μl PBS containing 3% FCS for
30 min at 4 °C, extensively washed and subsequently incubated
with RPE-conjugated goat-anti human IgG (Sigma) for 30 min at
4 °C before washes and ﬁxation. Stained cells were analyzed on a
FACStar device (Becton Dickinson).
Immunization of mice
BALB/c female mice, 6 to 8 weeks old, were purchased from the
Experimental Animal Center (Hunan, China). Animals were main-
tained under speciﬁc pathogen free (SPF) conditions, and randomly
divided into thirteen groups (9 mice per group). In vivo electropora-
tion was carried out according to the method described previously
(Aihara and Miyazaki, 1998). Mice were immunized with plasmid
DNA dissolved in 30 μl of PBS at a dosage of 30 μg WT, glycan mutant
DNA or vector pcDNA3.1 by injection into the quadriceps muscles.
After injection in the right quadriceps muscle, a pair of electrode nee-
dles 5 mm apart was inserted into the muscle to cover the DNA injec-
tion sites and electric pulses were delivered using the ECM 830
Square Wave Electroporation System (BTX). Three pulses of 100 V
each, followed by three pulses of the opposite polarity, were deliv-
ered to each injection site at a rate of one pulse per second. Each
pulse lasted for 50 ms. All mice were vaccinated three times in
3 week intervals. After the ﬁnal immunization, mice were bled from
the orbital sinus. All animals were handled in strict accordance with
good animal practice as deﬁned by the Hubei Laboratory Animal Sci-
ence Association and all animal work was approved by the Institu-
tional Animal Care and Use Committee (Approval ID: S03409100L
and S03409110D).
Measurement of Ab levels by ELISA
To detect the level of Env speciﬁc IgG,plates were coated with
50 μl of 5.0 μg/ml trimeric CN54 gp140 overnight as previous de-
scribed (Arias et al., 2011). After blocking with 300 μl per well of
PBS containing 1% BSA for 1 h at room temperature, the plates were
washed with PBS-T 3 times. Sera from different groups of the immu-
nized mice were added into the wells in a series of three-fold dilu-
tions. Following incubation at 37 °C for 1 h, the plates were washed
3 times and incubated with a 1/1000 dilution of horseradish
peroxidase-conjugated goat anti-mouse IgG (Abcam) in PBS-T. After5 washes, the reaction was developed with TMB (Sigma), stopped
with 2 M H2SO4, and absorbance was read at 450 nm by using an
ELISA plate reader (Tecan). Sample dilutions were considered posi-
tive if the OD recorded for that dilution was at least 2-fold higher
than the OD recorded for the control sample at the same dilution.
Endpoint titers were analyzed using GraphPad Prism 4 (GraphPad
Software).
Neutralization assay
The ability of serum neutralization was determined as previously
described (Monteﬁori, 2009). One day before the neutralization
assay, 6×103 TZM-bl cells per well were plated in 96-well plates.
Mice serum samples were heat-inactivated at 56 °C for 1 h and then
diluted (1:20 or 3-fold dilution of 1:20 to 1:540) in triplicates. Unless
otherwise indicated, 200 TCID50 (50% tissue culture infective dose)
pseudotyped viruses were incubated with diluted serum in a total
volume of 100 μl at 37 °C for 1 h. Cells incubated with viruses in the
absence of serum were used as positive control, while uninfected
cells were used as background control. Following 1 h incubation, the
mixture of virus and serum was added to TZM-bl cells in 100 μl of
DMEM containing DEAE (40 μg/ml). The luciferase activity of cell
lysates was determined 48 h post-infection.
Statistical analysis
Unless otherwise indicated, data were presented as means±
standard deviation (SD) or standard error of the mean (SEM). The
IC50 was determined using the Ricketts and Head equation by
Sigmaplot 11. The signiﬁcance of difference in the neutralization ac-
tivity between different groups was assessed by unpaired Student's
t-test. p value b0.05 was considered statistically signiﬁcant and
labeled as *, while p value b0.01 was labeled as **.
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